Antibodies against equine ALG during treatment of rejection crisis after renal allotransplantation.
The development of antibodies to equine anti-human-lymphocyte globulin (ALG) was followed using passive hemagglutination and gel diffusion, and to Forssman antigen using direct sheep erythrocyte agglutination, in a controlled clinical investigation of ALG treatment of established rejection of renal allografts in a total of 12 patients. With passive hemagglutination a weak antibody to ALG was seen only in one case. There was no increase in titer for sheep erythrocyte antigens during treatment, which agrees well with clinical observations in which no anaphylactic reactions were seen.
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D005260:Female; D006084:Graft Rejection; D006384:Hemagglutination; D006801:Humans; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D000906:Antibodies; D000961:Antilymphocyte Serum